|Bid||4.75 x 1200|
|Ask||4.94 x 900|
|Day's Range||4.6700 - 4.9200|
|52 Week Range||3.6200 - 9.4200|
|Beta (3Y Monthly)||1.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.10|
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that it has acquired the Somerset, NJ manufacturing facility for AZEDRA® (iobenguane I 131) for cash consideration of $8.0 million. AZEDRA is the first and only FDA-approved radiopharmaceutical indicated for the treatment of pheochromocytoma and paraganglioma, ultra-rare cancers.
NEW YORK, Jan. 22, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, and Curium today announced an exclusive agreement to develop and commercialize PyL in Europe. PyL is Progenics’ PSMA-targeted small molecule PET/CT imaging agent designed to visualize prostate cancer currently in Phase 3 development.
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced the appointment of Asha Das, M.D. to the newly created role of Chief Medical Officer. Dr. Das brings 13 years of drug development experience, including leading activities related to the approval and launch of Avastin® in multiple indications at Genentech, as well as a decade of clinical practice and academic expertise in neurology and neuro-oncology. “Asha is a talented clinician and a proven oncology drug development leader,” stated Mark Baker, CEO of Progenics. “Her experience developing and executing registrational studies will be invaluable to Progenics as we advance our portfolio of PSMA-targeted imaging and therapeutic agents and look to developing new indications for AZEDRA.
In 2011 Mark Baker was appointed CEO of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll Read More...
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that the first patient has been dosed in the Company’s Phase 3 CONDOR study evaluating the diagnostic performance and clinical impact of PyLTM (18F-DCFPyL) in men with biochemical recurrence of prostate cancer. Dr. Lawrence Saperstein, Assistant Professor of Radiology and Biomedical Imaging and Chief of Nuclear Medicine at Yale Smilow Cancer Hospital, and a principle investigator of the trial said, “PyL has demonstrated excellent positive and negative predictive values in detecting the presence or absence of prostate cancer.
NEW YORK, Nov. 19, 2018 -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and.
Progenics (PGNX) delivered earnings and revenue surprises of 50.00% and 28.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).
I am going to run you through how I calculated the intrinsic value of Progenics Pharmaceuticals Inc (NASDAQ:PGNX) by estimating the company’s future cash flows and discounting them to their Read More...
Progenics Pharmaceuticals' (PGNX) shares down on disappointing results from phase III study evaluating imaging agent, 1404, for prostate cancer detection.
NEW YORK, NY / ACCESSWIRE / September 14, 2018 / Both AbbVie and Progenics had data results this week for Wall Street to absorb. While shares of AbbVie saw gains on its data for Upadacitinib, an investigational oral agent engineered by the company to selectively inhibit JAK1 and is being studied as a once-daily therapy in atopic dermatitis, shares of Progenics were in the red on missing one endpoint in its phase 3 clinical trial testing of its prostate cancer imaging agent, 1404.
NEW YORK, NY / ACCESSWIRE / September 13, 2018 / U.S. markets were mixed on Wednesday as technology shares declined, dragging the Nasdaq into the red. The Dow Jones Industrial Average climbed 0.11 percent ...